1经典化疗药物biomarker分析报告.pptx

经典化疗药物生物标志物;Right people Right time;常规化疗药物疗效预测分子靶向化疗;The ERCC1 (excision repair cross-complementing 1) is a gene encoding a protein of the nucleotide excision repair (NER) complex, a group of proteins able to correct DNA damage induced by substances forming adducts, like platinum (Martin et al, 2008). High levels of ERCC1 protein have been shown to be a positive prognostic factor in chemotherapy-naive radically resected NSCLC (Olaussen et al, 2006; Zheng et al, 2007; Simon et al, 2008). ;DNA损伤修复途径的靶点;DNA修复机制是铂类耐药的主要因素;DNA加合物与旁路调节;ERCC1;Olaussen KA, Dunant A, Fouret P, et al. N Engl J Med. 2006 Sep 7;355(10):983-91. ;2011年NCCN指南（NSCLC）;BRCA1;BRCA1在DNA损伤修复中的作用;BRCA1同时预测铂类和紫杉类的疗效;RAP80协助BRCA1定位于DNA损伤部位;Rosell R, Perez-Roca L, Sanchez JJ, et al. PLoS One. 2009;4(5):e5133;常规化疗药物疗效预测分子靶向化疗;氟脲嘧啶类药物代谢途径;胸腺??啶磷酸化酶(TP);;Association of DPYD Genotypes With Isolated Types of Toxicity;TS基因多态与5-Fu疗效相关;TS（胸腺嘧啶核苷酸合成酶） ;;Association between genotypes and response to chemotherapy in the 80 patients ;;;常规化疗药物疗效预测分子靶向化疗;伊立替康与UGT1A1;UGT1A1*28与伊立替康副反应--迟发性腹泻/中性粒细胞减少的相关性;伊立替康与UGT1A1;UGT1A1 status correlation with irinotecan-associated toxicity and treatment efficacy;常规化疗药物疗效预测分子靶向化疗;β-微管蛋白与紫杉类药物;β微管蛋白基因突变诱发紫杉耐药;常规化疗药物疗效预测分子靶向化疗;蒽环类与抗TOP2药物的作用机制;TOP2α蛋白和基因;预后指标？;TOP2A;Biomarker不是靶向药物的专属;Thank you！